文献速递白血病

UKALL2003临床试验中缺乏遗传生物标志物的儿童急性淋巴细胞白血病的整合基因组分析

Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial.
PubMed 文献 · Leukemia · 2022-12-22

该研究对UKALL2003试验中351例B-other-ALL患儿整合二代测序(全基因组测序n=157、靶向测序n=175,重叠n=36)与已有遗传学注释,识别出PAX5alt、PAX5 P80R、DUX4-r、ETV6::RUNX1-like及ABL-class融合等亚型并验证其预后意义。

要点

  • PAX5alt最常见(n=91),PAX5 P80R突变(n=11)定义独立PAX5亚型。
  • DUX4-r亚型(n=80)复发率低、生存极佳;ETV6::RUNX1-like(n=21)无复发或死亡。
  • ABL-class融合(n=25)预后较差得到证实;二代测序可提升风险分层遗传亚型的检测与分类准确性。

核心结论

  • 在UKALL2003单试验内将二代测序整合入B-other-ALL基因组分析,显示基于二代测序的方法通过提高风险分层遗传亚型检测与分类的准确性而具有附加临床价值,并验证了其预后意义。

研究设计与样本

  • 研究纳入UKALL2003儿童ALL试验中351例B-other-ALL患者,整合二代测序(全基因组测序n=157、定制靶向二代测序n=175,重叠n=36)与已有遗传学注释。

主要发现

  • PAX5alt最常见(n=91),PAX5 P80R突变(n=11)定义独立PAX5亚型。
  • DUX4-r亚型(n=80)由DUX4重排和/或ERG缺失定义,这些患者复发率低且生存极佳。
  • ETV6::RUNX1-like亚型(n=21)以ETV6和IKZF1多重异常为特征,该试验中无复发或死亡报告,提示预后极佳。
  • ABL-class融合患者(n=25)的较差结局得到证实。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Incorporating genetics into risk-stratification for treatment of childhood B-progenitor acute lymphoblastic leukaemia (B-ALL) has contributed significantly to improved survival. In about 30% B-ALL (B-other-ALL) without well-established chromosomal changes, new genetic subtypes have recently emerged, yet their true prognostic relevance largely remains unclear. We integrated next generation sequencing (NGS): whole genome sequencing (WGS) (n = 157) and bespoke targeted NGS (t-NGS) (n = 175) (overlap n = 36), with existing genetic annotation in a representative cohort of 351 B-other-ALL patients from the childhood ALL trail, UKALL2003. PAX5alt was most frequently observed (n = 91), whereas PAX5 P80R mutations (n = 11) defined a distinct PAX5 subtype. DUX4-r subtype (n = 80) was defined by DUX4 rearrangements and/or ERG deletions. These patients had a low relapse rate and excellent survival. ETV6::RUNX1-like subtype (n = 21) was characterised by multiple abnormalities of ETV6 and IKZF1, with no reported relapses or deaths, indicating their excellent prognosis in this trial. An inferior outcome for patients with ABL-class fusions (n = 25) was confirmed. Integration of NGS into genomic profiling of B-other-ALL within a single childhood ALL trial, UKALL2003, has shown the added clinical value of NGS-based approaches, through improved accuracy in detection and classification into the range of risk stratifying genetic subtypes, while validating their prognostic significance.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Schwab C, Cranston RE, Ryan SL, et al. Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial. Leukemia. 2022. PMID: 36550215. doi:10.1038/s41375-022-01799-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。